Role of mTOR in Hematological Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1875-6301|4|3|211-218

ISSN： 1573-3947

Source： Current Cancer Therapy Reviews, Vol.4, Iss.3, 2008-08, pp. : 211-218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of mTOR inhibitor in cholangiocarcinoma cell progression

By        

Oncology Letters, Vol. 7, Iss. 3, 2014-01 ,pp. : 854-860

Spandidos Publications

Access to resources Recommend Favorite

The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors

By  

Current Cancer Therapy Reviews, Vol. 4, Iss. 3, 2008-08 ,pp. : 227-234

Bentham Science Publishers

Access to resources Recommend Favorite

Role of IL9 and STATs in hematological malignancies (Review)

By Chen Na   Wang Xin  

Oncology Letters, Vol. 7, Iss. 3, 2014-03 ,pp. : 602-610

Spandidos Publications

Access to resources Recommend Favorite

Updates of mTOR Inhibitors

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 7, 2010-09 ,pp. : 571-581

Bentham Science Publishers

Access to resources Recommend Favorite

Les inhibiteurs de mTOR

By Cortot A.   Soria J.-C.  

Oncologie, Vol. 8, Iss. 9, 2006-11 ,pp. : 821-827

Springer Publishing Company

Access to resources Recommend Favorite